Phio Pharmaceuticals (PHIO)
(Delayed Data from NSDQ)
$5.05 USD
-0.80 (-13.60%)
Updated Jul 12, 2024 03:57 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.05 USD
-0.80 (-13.60%)
Updated Jul 12, 2024 03:57 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Zacks News
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
by Zacks Equity Research
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
by Zacks Equity Research
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
by Zacks Equity Research
Phio Pharmaceuticals Corp. (PHIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US
by Zacks Equity Research
The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.
Humana (HUM) Brings Affordable MA Plan to U.S. Veterans
by Zacks Equity Research
Humana (HUM) ties up with USAA Life to develop a Medicare Advantage plan that transcends the VA system to fetch added healthcare benefits for veterans.
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
by Zacks Equity Research
Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.
Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) collaborates with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to serve the healthcare needs of the Georgian communities more effectively.
KalVista (KALV) Stock Continues to Decline: Here's Why
by Zacks Equity Research
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.
Encompass Health (EHC) Plans Hospital to Aid Florida Footprint
by Zacks Equity Research
Encompass Health (EHC) unveils plans to fortify its U.S. presence via building a 50-bed inpatient rehabilitation hospital in The Villages, Florida.
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug
by Zacks Equity Research
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.